Another $23 Million to Recruit Star Stem Cell Scientists to California

California's $46 million effort to lure
stem cell research stars to the Golden State was expanded today by
another $23 million.
Directors of the stem cell agency
approved the funds on a 14-4-1 vote. CIRM directors Jeff Sheehy and
Francisco Prieto were among those opposing the move. Prieto declared,

“We are coming up against finite resources. We have better ways to spend
our money."

 Sheehy said that CIRM is contributing to inflation in stem cell science with its lucrative recruitment grants. 

Those supporting the expansion said that the grants have had a great impact on the field, not only bringing in individual scientists, but accompanying researchers in their labs along with grants from other sources.
The additional funds will go to
institutions that have not already benefited from one of the earlier
grants in the program. Up to four awards are expected to be made.
The CIRM staff proposal on the plan
said,

“A number of California institutions
have not yet been able to secure a confirmed Research Leadership
award but would benefit greatly from the recruitment of emerging or
established leaders in stem cell biology. Participation in the CIRM
program could bring additional, exceptional researchers to
California, strengthen and synergize with other efforts to build up
local sustained research communities in stem cell biology and
medicine and provide ongoing leadership at the cutting edge of
California regenerative medicine.”

All of the California institutions
involved with the winning researchers have representatives on the
governing board of the stem cell agency. They are not allowed, however, to vote
on grants to their institutions or researchers -- only on proposals such as today's $23 expansion.
Applications are due in January with
final approval scheduled for next May. The program is not open to
businesses.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/iJ66PTxTsX8/another-23-million-to-recruit-star-stem.html

Related Posts

Comments are closed.